Chemotherapy and New Drugs in Prostate Cancer
نویسندگان
چکیده
Prostate cancer (PrC) is the fourth most common cancer (for both sexes combined) and the second most common cancer in men (accounting for 15% of all new male cancer cases), with a worldwide incidence of approximately 1,111,200, a 5-year prevalence of 3,924,000, and a mortality incidence of 307,000 for the year 2012.1 Since the 1990s, the increasing use of prostate-specific antigen (PSA) testing has had a significant influence on incidence rates, much more so than on mortality rates.1 As diagnosis can be established very early in the disease, most cases of PrC are treated at a localised stage with very good 10-year relative survival and progression-free survival (PFS) rates.
منابع مشابه
Neoadjuvant chemotherapy in high-risk localized prostate cancer: a systematic review
Background: The rate of recurrence and mortality in high-risk prostate cancer remains high. On the other hand, the use of chemotherapy in metastatic prostate cancer has improved overall survival of patients. The aim of this study was to evaluate the effect of neoadjuvant chemotherapy alone on increasing survival of patients with high risk localized prostate cancer Methods: This is a systematic...
متن کاملEvaluation of Anti-cancer activity of Boswellic acid and Montelukast sodium against human prostate cancer cell line PC-3
Prostate cancer is a devastating disease for which current therapies are inadequate. Various lines of evidences have suggested the 5-lipoxygenase (5-LOX) pathway and the leukotriene receptor pathway are potential targets for prevention or treatment of Prostate cancer. Thus, search for new anti-cancer drugs targeting 5-LOX and leukotriene is very essential and important. The objective of the pre...
متن کاملKnockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy
The treatment of prostate cancer patients usually starts with androgen ablation and followed by chemotherapy; however, in some cases the tumor develops resistant phenotype. Combination therapy is currently regarded as a cornerstone in cancer therapy to overcome the drug resistance. Herein, we investigated the combinatory effect of Docetaxel and Trastuzumab with a novel nanomedicine, BCc1. Also,...
متن کاملMolecular mechanisms involved in multidrug resistance in breast cancer therapy
Breast cancer is the most prevalent cancer in women. Chemotherapy is the main strategy in the treatment of this disease especially in the advanced form of the disease. Despite the recent progress in the development of new chemotherapy, the effectiveness of these drugs has dramatically reduced due to multidrug resistance. The phenotype of multidrug resistance (MDR) can occur through different me...
متن کاملCost evaluation of chemotherapy and epidemiology of five most common cancers in Isfahan Province in Iran
Background: Cancer is the third leading cause of death in Iran. Cancer treatment is very costly and chemotherapy drugs are one of the main causes of the high cost of cancer treatment. The purpose of this study was to evaluate the cost of chemotherapy drugs of five most common cancers and identifying the factors might affect the costs of chemotherapy drugs in a one of the large provinces of Iran...
متن کاملFactors influencing hematologists-oncologists’ prescription of chemotherapy drugs in cancer treatment in Iran: aninterview-questionnaire study
Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, and targeted therapy. The choice of treatment dependson the type and stage of the cancer. Chemotherapy drugs play an important role in cancer treatment. The objective of this interview-questionnaire study is to explore what influences Iranian hematologists-oncologists’ prescription when prescribing chemotherapy...
متن کامل